Revenue, 2025

USD 5.8 Billion

Forecast, 2035

USD 12.41 Billion

CAGR, 2026-2035

7.9%

Report Coverage

Global

Clinical Trial Third Party Logistics Market Trends for 2026

The global clinical trial third-party logistics market size was estimated at USD 5.8 billion in 2025 and is predicted to increase from USD 6.26 billion in 2026 to approximately USD 12.41 billion by 2035, expanding at a CAGR of 7.9% from 2026 to 2035. The growing clinical trials and R&D activities are increasing the use of clinical trial third-party logistics. The expanding healthcare sector, decentralized trials, technological innovations, and new collaborations are also enhancing the market growth.

Key Takeaways

• Clinical trial third-party logistics market to crossed USD 6.26 billion by 2026.
• Market projected at USD 12.41 billion by 2035.
• CAGR of 7.9% expected in between 2026 to 2035.
• North America held the major revenue share of 38% and a CAGR of 7.40% in the global clinical trial third-party logistics market in 2025.
• Asia Pacific held 24% share of the market in 2025 and is expected to grow at the fastest CAGR of 9.1% during the forecast period.
• By service type, the transportation segment held a dominant revenue share of 34% of the market in 2025.
• By service type, the distribution & returns management segment held 18% of market share in 2025 and is expected to grow at the fastest CAGR of 8.6% during the forecast period.
• By temperature range type, the ambient segment held a dominant revenue share of 38% of the clinical trial third-party logistics market in 2025.
• By temperature range type, the ultra-low temperature (-70°C and below) segment held 10% of market share in 2025 and is expected to grow at the fastest CAGR of 9.5% during the forecast period.
• By phase type, the phase III segment held a dominant revenue share of 44% of the market in 2025 and is expected to grow at the fastest CAGR of 8.2% during the forecast period.
• By end user, the pharmaceutical companies segment held a dominant position in the market with a share of 46% in 2025.
• By end user, the biotechnology companies segment held the second-largest share of 24% of the clinical trial third-party logistics market in 2025 and is expected to grow at the fastest CAGR of 8.8% during the forecast period.
• By therapeutic area type, the oncology segment held a dominant revenue share of 36% of the market in 2025 and is expected to grow with the fastest CAGR of 8.7% during the forecast period.

What are the Clinical Trial Third Party Logistics?

The clinical trial third-party logistics market is driven by growing trial complexities and a shift towards specialized supply chain solutions. The clinical trial third-party logistics encompasses specialized logistic partners offering supply chain and logistics services. They help in safe and efficient storage, packing, labeling, and distribution of investigational drugs and clinical trial resources.

Why is the Demand for AI Increasing in the Market?

The demand for AI in the clinical trial third-party logistics market is increasing as it predicts the growth in the product demand, optimizes inventory, and prevents stockouts. It also helps in risk management and provides automated documentation, reducing the chances of errors. Its real-time monitoring, smart packaging, and regulatory compliance also increase its use.

What are the Trends & Future Outlook of the Market?

Globalization of Clinical Trials

The rise in the multi-country trials, multisite trials, and decentralized trials is increasing the demand for clinical trial third-party logistics for regulatory compliance and product distribution.

Flourishing Biologics

The growing advancements in biologics are increasing the use of clinical trial third-party logistics for their specialized storage, packaging, handling, and transportation solutions.

Growing R&D Investment

The rise in R&D investments is accelerating the development of new drug candidates and clinical trials, driving the demand for clinical trial third-party logistics for clinical supply management, logistics support, and packaging and labelling.

Key Indicators and Highlights

Segmental Insights

By Service Type Insights

The Transportation Segment Dominated the Market With 34% in 2025

The transportation segment led the clinical trial third-party logistics market with 34% share in 2025, due to growth in the clinical trials, which increased the demand for cross-border shipments. The presence of advanced tracking systems also increased their use. Additionally, faster delivery timelines also increased their demand.

The storage & warehousing segment held 22% of the market share in 2025, driven by increasing advancements in biologics development. This is increasing the demand for specialized storage conditions, increasing the use of clinical trial third-party logistics. Growing decentralized trials and regulatory requirements are also increasing their use.

The distribution & returns management segment held 18% of the clinical trial third-party logistics market share in 2025 and is expected to witness the fastest growth with a CAGR of 8.6% during the forecast period, due to their real-time distribution optimization, which improves trial efficiency. The growing decentralized trials are also increasing the demand for direct-to-patient logistics. The growth in reverse logistics grows with unused drug returns, which are also increasing in use.

The packaging & labeling segment held 14% of the market share in 2025, due to growing demand patient centric packaging to enhance compliance and safety. The growing development of biologics is also increasing the demand for specialized packaging. Moreover, growing decentralized trials are also increasing direct-to-patient logistics.

By Temperature Range Insights

The Ambient Segment Dominated the Market With 38% in 2025

The ambient segment accounted for the highest revenue share of 38% of the clinical trial third-party logistics market in 2025, driven by its affordability and simpler handling. The growth in the volume of conventional drugs also increased their adoption rates. Moreover, their simple transportation and faster delivery also increased their use.

The refrigerated (2–8°C) segment held 34% of the market share in 2025, due to growing development of biologics and vaccines. The growing clinical trials of the specialty drugs are also increasing their use. Stringent stability requirements and expansion of cold chain infrastructure are also increasing their use.

The frozen (-20°C and below) segment held 18% of the clinical trial third-party logistics market share in 2025, due to growing advanced therapies, which increase the demand for frozen storage conditions. The rise in the clinical trials of biologics has also increased their demand. Furthermore, increasing advancements in freezing technologies are also increasing their acceptance rates.

The ultra-low temperature (-70°C and below) segment held 10% of market share in 2025 and is expected to show the highest growth with a CAGR of 9.5% during the forecast period, due to growing investments in ultra-cold logistics. The rise in mRNA and cell therapies is also increasing their use. Additionally, expanding infrastructure due to pandemic-driven innovations is also increasing their use.

By Phase Insights

The Phase III Segment Dominated the Market With 44% in 2025

The phase III segment held a major revenue share of 44% of the clinical trial third-party logistics market in 2025 and is expected to expand rapidly with a CAGR of 8.2% during the forecast period, driven by high investment in late-stage trials. The growth in the large-scale global trials also increased the demand for extensive logistics support. The expansion of the multi-country studies also increased the transportation demand.

The phase II segment held 22% of the market share in 2025, due to pipeline progression, which increases trial complexity and demand for third-party logistics. The patient recruitment expansion also drives logistics needs. The growing mid-scale logistics are also attracting companies.

The phase IV segment held 18% of the clinical trial third-party logistics market share in 2025, driven by the distribution to broader patient populations and growth in decentralized trials. The focus on real-world evidence is also increasing its use. The growing long-term studies are also increasing the demand for sustained logistics support.

The phase I segment held 16% of the market share in 2025, as Early-stage trials increase demand for small batch logistics. The growing biotech startups and rapid study cycles are also increasing their use. Additionally, the growing development of personalized medicines is also increasing their demand.

By End User Insights

The Pharmaceutical Companies Segment Dominated the Market With 46% in 2025

The pharmaceutical companies segment contributed the biggest revenue share of 46% of the clinical trial third-party logistics market in 2025, due to high R&D investments, which increased the use of clinical trial third-party logistics. The growth in the drug pipeline also increased logistics demand. The expansion of the trial networks also increased shipment needs.

The biotechnology companies segment held the second-largest share of 24% of the market in 2025 and is expected to gain the highest share with a CAGR of 8.8% during the forecast period, due to growth in biologics and gene therapies. Growing outsourcing trends also increase the demand for logistics support. Increasing innovation-driven trials are also increasing the demand for specialized handling.

The contract research organizations (CROs) segment held 20% of the clinical trial third-party logistics market share in 2025, due to growth in outsourcing trends. The integrated trial services are also driving demand. Expanding CRO networks are increasing collaborations to leverage the logistic services.

The academic & research institutes segment held 10% of the market share in 2025, driven by expanding R&D activities. Limited internal logistics capabilities are also increasing the demand for clinical trial third-party logistics. Increasing government-funded trials are also promoting their use.

By Therapeutic Area Insights

The Oncology Segment Dominated the Market With 36% in 2025

The oncology segment held the largest revenue share of 36% of the clinical trial third-party logistics market in 2025 and is expected to grow with the fastest CAGR of 8.7% during the forecast period, driven by growth in the demand for complex logistic support due to the rise in cancer trials. High investments also fuel their demand. Growth in personalized therapy also increased their use for storage and handling support.

The infectious diseases segment held 18% of the market share in 2025, due to the rise in vaccine trials. Growing global health initiatives are also increasing the demand for cold chain logistics. A rise in the patient value is also driving the demand for clinical trial third-party logistics.

The cardiovascular diseases segment held 14% of the clinical trial third-party logistics market share in 2025, due to growing incidence rates. The growing number of clinical trials is also increasing the demand for clinical trial third-party logistics. Growing adoption of standardised therapies is also increasing their use.

The neurology segment held 12% of the market share in 2025, due to neurodegenerative research and clinical trials. Their complex protocols are also increasing the demand for clinical trial third-party logistics. Rise in the disease incidence rates and geriatric population are also increasing the use of their treatment option, fueling the demand for logistic support.

Regional Insights

Strong Clinical Trial Infrastructure Drives North America

North America dominated the clinical trial third-party logistics market with 38% in 2025, due to the presence of a robust clinical trial infrastructure, which increased the use of clinical trial third-party logistics. The advanced cold chain capabilities also increased their demand. High R&D spending also increased their use, which contributed to the market growth.

U.S. Market Trends

The U.S. consists of large pharmaceutical and biotechnology companies, where the high R&D expenditure is increasing the use of clinical trials and third-party logistics. Stringent regulations and expanding clinical trials are also driving their adoption rates. Moreover, growing technological innovations are enhancing various features of logistics solutions.

Expanding Healthcare Boost Asia Pacific

Asia Pacific held 24% share of the clinical trial third-party logistics market in 2025 and is expected to show the highest growth with a CAGR of 9.1% during the forecast period, due to expanding healthcare infrastructure, which is driving the demand for clinical trial third-party logistics. A large patient population is increasing clinical trials, fueling their use. Additionally, expanding industry and R&D activities are also promoting the market growth.

China Market Trends

China is experiencing a rise in clinical trials, which is increasing the use of third-party clinical trial logistics. The presence of large patient pollution and expanding cold chain infrastructure is also fuelling their demand. Additionally, growing government support is also promoting their use.

Market Value Chain Analysis

R&D

• The R&D of the clinical trial third-party logistics focuses on the utilization of AI-driven predictive analytics and IoT-enabled real-time monitoring.
• Key players: Kuehne+Nagel, DHL, UPS.

Clinical Trials and Regulatory Approvals

• The GxP compliance and temperature integrity are evaluated in the clinical trial and regulatory approvals of the clinical trial third party logistics.
• Key players: World Courier, FedEx, Marken.

Patient Support and Services

• The specialized direct-to-patient (DTP) delivery and home nursing services are provided in the patient support and services of the clinical trial third-party logistics.
• Key players: Marken, World Courier.

Top Vendors and Their Offerings

SWOT Analysis

Strengths

• The clinical trial third-party logistics offer regulatory expertise that helps in maintaining regulatory compliance.
• It also offers global distribution capabilities, increasing its use in various clinical trials.
• Its specialized packaging, labelling, and cold chain management services are also increasing their use for specialty product storage and transportation.
• Real-time tracking and monitoring are also increasing in use.

Weaknesses

• High cost associated with specialised packaging, regulatory compliance, and cold chain services acts as the major weakness in the clinical trial third-party logistics market, limiting their use.
• High dependence on pharmaceutical and biotechnology companies also restricts their growth.

Opportunities

• The growing development of biologics and advanced therapies is increasing the demand for clinical trial third-party logistics.
• Expanding decentralized trials are also increasing their use.
• The growing development of personalized medicines is also increasing their use.
• Additionally, growing technological innovations are driving the advancements in clinical trial third-party logistics services.

Threats

• Supply chain disruption delays the drug production rates, reducing the use of clinical trial third-party logistics services.
• Limited manufacturing capability also slows down the development of high-demand drugs, limiting their use.

What are the Recent Developments in the Market?

• In October 2025, to revolutionize the global delivery of temperature-controlled pharmaceuticals, a collaboration between Frontier Scientific Solutions (Frontier) and Air Transport Services Group, Inc. (ATSG) was announced, where they will provide a dedicated air corridor with continuous temperature control and full shipment integrity throughout the transportation.
• In April 2025, the Brazil-to-USA lane was added to the enhanced Medical Express (WMX) service of DHL Express, which will support the customers in the clinical research and pharmaceutical sectors by mitigating the risk of complex supply chain navigation, which is essential for clinical trials and medical research.

Segments Covered in the Report

By Service Type

• Transportation
  • Air Freight
  • Sea Freight
  • Road Transport
• Storage & Warehousing
• Ambient Storage
• Cold Chain Storage
  • Refrigerated (2–8°C)
  • Frozen (-20°C and below)
• Packaging & Labeling
  • Primary Packaging
  • Secondary Packaging
  • Clinical Labeling
• Distribution & Returns Management
  • Direct-to-Site Distribution
  • Depot Distribution
  • Reverse Logistics
• Ancillary Services
  • Comparator Sourcing
  • Inventory Management
  • Regulatory Compliance Support

By Temperature Range

• Ambient
• Refrigerated (2–8°C)
• Frozen (-20°C and below)
• Ultra-Low Temperature (-70°C and below)

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes

By Therapeutic Area 

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Neurology
• Rare Diseases
• Others

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA